z-logo
open-access-imgOpen Access
Podocyte Regeneration Driven by Renal Progenitors Determines Glomerular Disease Remission and Can Be Pharmacologically Enhanced
Author(s) -
Laura Lasagni,
Maria Lucia Angelotti,
Elisa Ronconi,
Duccio Lombardi,
Sara Nardi,
Anna Julie Peired,
Francesca Becherucci,
Benedetta Mazzinghi,
Alessandro Sisti,
Simone Romoli,
Alexa Burger,
Beat Schaefer,
Annamaria Buccoliero,
Elena Lazzeri,
Paola Romagnani
Publication year - 2015
Publication title -
stem cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.207
H-Index - 76
ISSN - 2213-6711
DOI - 10.1016/j.stemcr.2015.07.003
Subject(s) - podocyte , biology , progenitor cell , glomerulosclerosis , kidney disease , focal segmental glomerulosclerosis , regeneration (biology) , minimal change disease , progenitor , glomerulonephritis , kidney , cancer research , population , disease , medicine , endocrinology , immunology , stem cell , microbiology and biotechnology , proteinuria , environmental health
Podocyte loss is a general mechanism of glomerular dysfunction that initiates and drives the progression of chronic kidney disease, which affects 10% of the world population. Here, we evaluate whether the regenerative response to podocyte injury influences chronic kidney disease outcome. In models of focal segmental glomerulosclerosis performed in inducible transgenic mice where podocytes are tagged, remission or progression of disease was determined by the amount of regenerated podocytes. When the same model was established in inducible transgenic mice where renal progenitors are tagged, the disease remitted if renal progenitors successfully differentiated into podocytes, while it persisted if differentiation was ineffective, resulting in glomerulosclerosis. Treatment with BIO, a GSK3s inhibitor, significantly increased disease remission by enhancing renal progenitor sensitivity to the differentiation effect of endogenous retinoic acid. These results establish renal progenitors as critical determinants of glomerular disease outcome and a pharmacological enhancement of their differentiation as a possible therapeutic strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom